Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX STOCKHOLM  >  Probi AB (publ)    PROB   SE0001280355

PROBI AB (PUBL)

(PROB)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

Probi publ : Presentation of Probi's Q2 report 2020 and new financial targets

07/14/2020 | 02:31am EST

Probi's report for the second quarter 2020 and the new financial targets will be published on Friday, 17 July at 8.00 a.m. CET.

In conjunction with this, analysts, investors and media are invited to an audiocast telephone conference on the same day at 10.00 a.m., where CEO Tom Rönnlund and CFO Henrik Lundkvist will present and comment on the report. The presentation and presentation material can be obtained via www.probi.com (http://www.probi.se) or https://tv.streamfabriken.com/probi-q2-2020

The presentation can also be followed via a telephone conference on the following telephone number:
Sweden: + 46 8 50 55 83 59
UK: +44 33 33 00 92 69
US: + 1 83 35 26 83 96

After the presentation, conference participants will be able to ask questions. Questions can also be asked via the audiocast.

An on-demand version of the presentation will be available at the address given above following the presentation.

FOR FURTHER INFORMATION, CONTACT:
Henrik Lundkvist, CFO, Probi, tel +46 46 286 89 41, e-post: henrik.lundkvist@probi.com

ABOUT PROBI
Probi AB is a Swedish publicly traded bioengineering company. Probi's vision is to help people live healthier lives by delivering effective and well-documented probiotics, with proven health benefits based on scientific research. Founded by scientists in Sweden in 1991, Probi is a multinational company, active in more than 40 markets around the world and holding over 400 patents worldwide. In 2019, Probi had net sales of MSEK 626. The Probi share is listed on Nasdaq Stockholm, Mid Cap. Probi had about 4,000 shareholders on December 31, 2019. Read more at www.probi.com.

https://news.cision.com/probi/r/presentation-of-probi-s-q2-report-2020-and-new-financial-targets,c3153395

https://mb.cision.com/Main/1556/3153395/1278655.pdf

(c) 2020 Cision. All rights reserved., source Press Releases - English

Stocks mentioned in the article
ChangeLast1st jan.
PROBI AB (PUBL) 0.11% 471.5 Delayed Quote.11.61%
SYMRISE AG 1.30% 101 Delayed Quote.-6.83%
All news about PROBI AB (PUBL)
01/15PROBI : Truths, Facts and Why Probiotics Matter (IPA webinar for media)
AQ
2020Q3 2020 : Strong growth with good profitability
AQ
2020PROBI : acquires shares in Vital Nutrients Holdings and enters into strategic pa..
AQ
2020PROBI : Presentation of Probi's Q3 report
AQ
2020PROBI : New clinical results on stress from Probi and their probiotic strain L. ..
AQ
2020Q2 2020 : Probi raises long-term financial targets
AQ
2020PROBI PUBL : Presentation of Probi's Q2 report 2020 and new financial targets
PU
2020PROBI PUBL : Presentation of Probi's Q2 report 2020 and new financial targets
AQ
2020PROBI PUBL : and Örebro University to collaborate on research into exploration o..
AQ
2020PROBI PUBL : A true pioneer in probiotic research is elected NutraChampion 2020
AQ
More news
Financials
Sales 2020 711 M 85,3 M 85,3 M
Net income 2020 102 M 12,2 M 12,2 M
Net cash 2020 259 M 31,1 M 31,1 M
P/E ratio 2020 53,0x
Yield 2020 0,33%
Capitalization 5 372 M 643 M 644 M
EV / Sales 2020 7,19x
EV / Sales 2021 6,62x
Nbr of Employees -
Free-Float 39,3%
Chart PROBI AB (PUBL)
Duration : Period :
Probi AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PROBI AB (PUBL)
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
 
Mean consensus -
Number of Analysts 2
Average target price 440,00 SEK
Last Close Price 471,50 SEK
Spread / Highest target -6,68%
Spread / Average Target -6,68%
Spread / Lowest Target -6,68%
EPS Revisions
Managers and Directors
NameTitle
Tom Juhani Rönnlund Chief Executive Officer
Jean-Yves Parisot Chairman
Andy McShea Vice President-Operations
Henrik Lundkvist Chief Financial Officer
Niklas Brandt Vice President-Information Technology
Sector and Competitors
1st jan.Capitalization (M$)
PROBI AB (PUBL)11.61%640
BY-HEALTH CO., LTD.0.54%5 918
BALCHEM CORPORATION6.01%3 952
THE SIMPLY GOOD FOODS COMPANY-10.71%2 680
MEDIFAST, INC.6.23%2 444
BIOGAIA AB (PUBL)-4.66%1 233